✦ LIBER ✦

Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer

✍ Scribed by Allan Lipton; Laurence M. Demers; Harold A. Harvey; Kathleen B. Kambic; Howard Grossberg; Carolyn Brady; H. Adlercruetz; Patrick F. Trunet; Richard J. Santen

Book ID: 102672642
Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 663 KB
Volume: 75
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19950415)75:8<2132::aid-cncr2820750816>3.0.co;2-u

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of Fadrozole (CGS 16949A) and Le

Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients

✍ Laurence M. Demers 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 672 KB

A phase I trial of CGS 16949a. A new aro

A phase I trial of CGS 16949a. A new aromatase inhibitor

✍ Allan Lipton; Harold A. Harvey; Laurence M. Demers; John R. Hanagan; Mary T. Mul 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 632 KB

CGS 16949A is a new, nonsteroidal competitive inhibitor of the aromatase enzyme. In this Phase I trial, 16 heavily pretreated postmenopausal patients with metastatic breast cancer were treated with escalating doses of CGS 16949A from 0.6 to 16 mg total daily oral dose. No hematologic, biochemical, o

Effect of the potent aromatase inhibitor

Effect of the potent aromatase inhibitor letrozole on lipid parameters in postmenopausal women with breast cancer

✍ E. Bairaktari; M. Elisaf; K. Nikolaides; V. Kakaidi; A. Katsaraki; N. Pavlides 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 280 KB

373 Phase II trial of letrozole (a novel

373 Phase II trial of letrozole (a novel oral nonsteroidal aromatase inhibitor) in postmenopausal patients with advanced or recurrent breast cancer

✍ T. Tominaga; Y. Ohashi; R. Abe; M. Yoshida; H. Koyama; Y. Nomura; A.S. Bhatnagar 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 153 KB

The oral mTOR inhibitor RAD001 (everolim

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics

✍ Ahmad Awada; Fatima Cardoso; Christel Fontaine; Luc Dirix; Jacques De Grève; Chr 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 175 KB

A phase II study of a potent and selecti

A phase II study of a potent and selective aromatase inhibitor, anastrozole (ZD-1033), in Japanese postmenopausal women with advanced/recurrent breast cancer

✍ H. Koyama 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 147 KB